MX2020012350A - Anticuerpos anti-cd63, conjugados y usos de estos. - Google Patents
Anticuerpos anti-cd63, conjugados y usos de estos.Info
- Publication number
- MX2020012350A MX2020012350A MX2020012350A MX2020012350A MX2020012350A MX 2020012350 A MX2020012350 A MX 2020012350A MX 2020012350 A MX2020012350 A MX 2020012350A MX 2020012350 A MX2020012350 A MX 2020012350A MX 2020012350 A MX2020012350 A MX 2020012350A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- conjugates
- same
- patient
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
- C12N9/2411—Amylases
- C12N9/2428—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan anticuerpos, partes y proteínas de fusión de estos contra CD63. También se proporcionan secuencias de ácidos nucleicos que los codifican. También se proporcionan composiciones que los comprenden y métodos para su uso, por ejemplo, para tratar a un paciente que lo necesita.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862673098P | 2018-05-17 | 2018-05-17 | |
US201862681563P | 2018-06-06 | 2018-06-06 | |
US201862777592P | 2018-12-10 | 2018-12-10 | |
PCT/US2019/032922 WO2019222663A1 (en) | 2018-05-17 | 2019-05-17 | Anti-cd63 antibodies, conjugates, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020012350A true MX2020012350A (es) | 2021-01-29 |
Family
ID=66691071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020012350A MX2020012350A (es) | 2018-05-17 | 2019-05-17 | Anticuerpos anti-cd63, conjugados y usos de estos. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210079109A1 (es) |
EP (1) | EP3793591A1 (es) |
JP (1) | JP7477462B2 (es) |
KR (1) | KR20210010916A (es) |
CN (1) | CN112135624B (es) |
AU (1) | AU2019269685A1 (es) |
BR (1) | BR112020023145A2 (es) |
CA (1) | CA3100021A1 (es) |
CL (3) | CL2020002965A1 (es) |
CO (1) | CO2020015052A2 (es) |
MA (1) | MA52626A (es) |
MX (1) | MX2020012350A (es) |
PH (1) | PH12020551955A1 (es) |
SG (1) | SG11202011232VA (es) |
WO (1) | WO2019222663A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL314482A (en) | 2022-02-02 | 2024-09-01 | Regeneron Pharma | Anti-TFR:GAA and anti-CD63:GAA insertions for the treatment of Pompe disease |
WO2023194501A1 (en) * | 2022-04-05 | 2023-10-12 | Altheia Science S.R.L. | Treatment of myeloid disorders and acute leukemias targeting novel tumor specific antigens |
CN116041520B (zh) * | 2022-12-28 | 2023-09-22 | 武汉爱博泰克生物科技有限公司 | 针对Human CD63的兔单克隆抗体及其制备方法和应用 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
EP1086223B1 (en) | 1998-06-01 | 2009-07-29 | Agensys, Inc. | Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
US7375078B2 (en) | 2004-02-23 | 2008-05-20 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
MY159787A (en) | 2006-06-02 | 2017-01-31 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
CA2687178C (en) | 2007-05-23 | 2014-02-04 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
SG189817A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
EP2326349B1 (en) | 2008-07-21 | 2015-02-25 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
MX342623B (es) | 2009-06-26 | 2016-10-06 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
EP2549276B1 (en) | 2009-08-10 | 2015-02-25 | UCL Business PLC | Reversible covalent linkage of functional molecules |
NZ719253A (en) | 2010-02-08 | 2022-08-26 | Regeneron Pharma | Common light chain mouse |
EP2528625B1 (en) | 2010-04-15 | 2013-07-10 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2012005982A2 (en) | 2010-07-06 | 2012-01-12 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Reporter for rna polymerase ii termination |
US8642835B2 (en) | 2011-02-25 | 2014-02-04 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
CA2837167A1 (en) | 2011-05-27 | 2012-12-06 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
JP6166728B2 (ja) | 2011-10-14 | 2017-07-19 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体 |
KR101961976B1 (ko) | 2011-10-14 | 2019-03-25 | 시애틀 지네틱스, 인크. | 피롤로벤조디아제핀 및 표적 접합체 |
EP2751111B1 (en) | 2011-10-14 | 2017-04-26 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases |
ES2945932T3 (es) | 2011-10-14 | 2023-07-10 | Seagen Inc | Pirrolobenzodiazepinas y conjugados dirigidos |
WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
CA2857398A1 (en) | 2011-12-05 | 2013-06-13 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
BR112014015238B1 (pt) | 2011-12-20 | 2022-11-16 | Regeneron Pharmaceuticals, Inc | Método ex vivo para preparar um anticorpo que se liga a um antígeno de interesse compreendendo identificar sequências de ácido nucleico a partir de linfócitos b de camundongo geneticamente modificado pela colocação de um gene adam6 |
DK2825553T3 (en) * | 2012-03-14 | 2018-09-24 | Regeneron Pharma | : Multispecific antigen binding molecules and applications thereof |
EP2911699B1 (en) | 2012-10-23 | 2017-11-15 | SynAffix B.V. | Modified antibody, antibody-conjugate and process for the preparation thereof |
TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
CA2901978A1 (en) | 2013-02-20 | 2014-08-28 | Valerion Therapeutics, Llc | Methods and compositions for treatment of pompe disease |
EP3964237A1 (en) | 2013-03-15 | 2022-03-09 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
MX2016002149A (es) | 2013-08-26 | 2016-10-28 | Regeneron Pharma | Composiciones farmaceuticas que contienen diasteromeros macrolidos, metodos para su sintesis y usos terapeuticos. |
CN107995912A (zh) | 2015-03-27 | 2018-05-04 | 里珍纳龙药品有限公司 | 美登素类衍生物、其偶联物和使用方法 |
AU2017211120C1 (en) | 2016-01-25 | 2021-10-07 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
US20190352423A1 (en) * | 2016-02-05 | 2019-11-21 | Genmab A/S | Multispecific antigen-binding molecule with improved internalization characteristics |
AU2018281280A1 (en) * | 2017-06-07 | 2020-01-16 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
EP3749373A1 (en) * | 2018-02-07 | 2020-12-16 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for therapeutic protein delivery |
-
2019
- 2019-05-17 SG SG11202011232VA patent/SG11202011232VA/en unknown
- 2019-05-17 CA CA3100021A patent/CA3100021A1/en active Pending
- 2019-05-17 KR KR1020207036307A patent/KR20210010916A/ko active Search and Examination
- 2019-05-17 CN CN201980032750.8A patent/CN112135624B/zh active Active
- 2019-05-17 MA MA052626A patent/MA52626A/fr unknown
- 2019-05-17 BR BR112020023145-2A patent/BR112020023145A2/pt unknown
- 2019-05-17 US US17/056,301 patent/US20210079109A1/en active Pending
- 2019-05-17 JP JP2020564394A patent/JP7477462B2/ja active Active
- 2019-05-17 AU AU2019269685A patent/AU2019269685A1/en active Pending
- 2019-05-17 MX MX2020012350A patent/MX2020012350A/es unknown
- 2019-05-17 EP EP19728288.2A patent/EP3793591A1/en active Pending
- 2019-05-17 WO PCT/US2019/032922 patent/WO2019222663A1/en active Application Filing
-
2020
- 2020-11-16 CL CL2020002965A patent/CL2020002965A1/es unknown
- 2020-11-16 PH PH12020551955A patent/PH12020551955A1/en unknown
- 2020-11-30 CO CONC2020/0015052A patent/CO2020015052A2/es unknown
-
2022
- 2022-01-13 CL CL2022000094A patent/CL2022000094A1/es unknown
-
2024
- 2024-02-08 CL CL2024000387A patent/CL2024000387A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3793591A1 (en) | 2021-03-24 |
CN112135624B (zh) | 2024-07-19 |
AU2019269685A1 (en) | 2020-12-03 |
CL2022000094A1 (es) | 2023-02-24 |
CL2020002965A1 (es) | 2021-08-06 |
CO2020015052A2 (es) | 2020-12-10 |
PH12020551955A1 (en) | 2021-08-16 |
SG11202011232VA (en) | 2020-12-30 |
US20210079109A1 (en) | 2021-03-18 |
WO2019222663A1 (en) | 2019-11-21 |
CA3100021A1 (en) | 2019-11-21 |
MA52626A (fr) | 2021-03-24 |
CL2024000387A1 (es) | 2024-07-05 |
JP7477462B2 (ja) | 2024-05-01 |
CN112135624A (zh) | 2020-12-25 |
KR20210010916A (ko) | 2021-01-28 |
JP2021524231A (ja) | 2021-09-13 |
BR112020023145A2 (pt) | 2021-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
PH12020551955A1 (en) | Anti-cd63 antibodies, conjugates, and uses thereof | |
MX2023007045A (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos. | |
MX2024004646A (es) | Proteinas de union de cadena unica de fragmento variable cd3. | |
PH12019500596A1 (en) | Recombinant binding proteins and their use | |
MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
PH12018502538A1 (en) | Antibodies to alpha-synuclein and uses thereof | |
MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
MD4716B1 (ro) | Anticorpi anti-LAG3 şi fragmente de legare a antigenului | |
EA201100070A1 (ru) | Туберкулезный белок rv2386c, композиции и их применения | |
MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
EA201792466A1 (ru) | АНТИТЕЛА ПРОТИВ FcRn | |
EA201100072A1 (ru) | Новые композиции и способы | |
UA107180C2 (uk) | Туберкульозний білок rv1753c, композиція, що його містить, та застосування | |
NZ713602A (en) | Method for refining protein including self-cutting cassette and use thereof | |
MX2022002315A (es) | Anticuerpos anti-cd96 y sus metodos de uso. | |
MX2015000754A (es) | Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. | |
MX2021011330A (es) | Anticuerpos de claudina-6 y conjugados de fármacos. | |
PH12020550483A1 (en) | Anti-apoc3 antibodies and methods of use thereof | |
SV2017005545A (es) | Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y metodos para usar los mismos | |
TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
CR20200642A (es) | Proteínas inmunodominantes y fragmentos en esclerosis múltiples | |
EA202190267A1 (ru) | Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака | |
PH12019502449A1 (en) | Anti-jagged1 antigen binding proteins | |
MX2022003523A (es) | Proteinas de union a antigenos. |